Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2017-08-29
2018-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An optimization of the management of pain in urgency is therefore still necessary.
A side from nitrousoxide of which usage remains restrictive, methoxyflurane (Penthrox®) is the only volatile analgesic currently available for pre-hospital use.
The purpose of this study is to answer the question: Does the use of the inhaled route with Penthrox add value to the treatment of acute traumatic pain in the pre-hospital stage?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Methoxyflurane (Penthrox) as an Antalgic in Hospital Trauma
NCT03927729
Trauma Acute Pain Treatment With Methoxyflurane Vaporized (PENTHROX®): Efficacy and Safety Study (MEDITA)
NCT03585374
Efficacy and Safety of Penthrox® Combined With a Standard Analgesia (SoC) in Adult Patients Admitted to the Emergency Department With Moderate to Severe Pain Associated With Trauma
NCT03798899
Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma
NCT01420159
A Pilot Study on the Use of Methoxyflurane (Penthrox®) for Pain Control in the Emergency Department
NCT04618497
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An optimization of the management of pain in urgency is therefore still necessary.
A side from nitrousoxide of which usage remains restrictive, methoxyflurane (Penthrox®) is the only volatile analgesic currently available for pre-hospital use.
Methoxyflurane (Penthrox®) is a single-use inhalation non-opioid analgesic for the management of moderate to severe traumatic pain. This treatment has been used in New Zealand and Canada for over 20 years for the management of acute pain in adults and children. It was granted marketing authorization in Europe in 2016 and has been marketed in France since 2017.
The purpose of this study is:
* To study the efficacy and safety of Penthrox, administrated at the beginning of the management of the traumatized adult patient.
* Assess the comfort of patients and caregivers
* To answer the question: Does the use of the inhaled route with Penthrox add value to the treatment of acute traumatic pain in the pre-hospital stage?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Penthrox
Administration of Penthrox at the beginning of the management of the traumatized adult patient
Penthrox
Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Penthrox
Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Acute pain only of traumatic origin
* Pain \> 4 on a visual numerical scale (VNS)
* Stable hemodynamic conditions (PA\> 90/60)
* Pregnant or nursing woman
* Patient who has already received analgesics
* Patient benefiting from an intravenous approach for analgesia
* Known renal or hepatic disease
* Hypersensitivity to fluorinated anesthetics or history of malignant hyperthermia of the patient or family.
* Respiratory distress
* Patient who objected to the processing of his data
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emergency Medical Service, University Hospital, Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A01077-46
Identifier Type: OTHER
Identifier Source: secondary_id
RIPH3-RNI17/UPETEH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.